Beclometasone & formoterol & glycopyrronium (Trimbow)
- BNF:
- Respiratory
- Status:
- Grey
- Decision Date:
- None
Comments
COPD (Trimbow 88/5/9 NEXThaler DPI): GREY 1st line
triple combination
COPD (Trimbow 87/5/9 MDI): GREY (Decision date - October 2017)
Indicated for the maintenance treatment of moderate to severe COPD
- Triple therapy is reserved
for exceptional use in severe disease in the presence of persistent exacerbation's despite other treatments.
- Triple therapy in a single
inhaler may be preferable for people who have difficulty using more than
one device or who find their medication regimen difficult or confusing,
and have trouble complying with treatment. However triple therapy lack
flexibility and makes it difficult to amend the individual medicines if
treatment needs changing for any reason.
- Use of this combination
product is cheaper than using the separate components.
Asthma (Trimbow 87/5/9 MDI and Trimbow 172/5/9 MDI): GREY after specialist initiation: to be used in severe asthma with a
demonstrated airflow obstruction. (Decision date - August 2021)
Grey Drug Classifications
- 8. Exceptionality where a small cohort of patients may benefit from prescribing can be identified
search again